Vaborbactam

Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada

Retrieved on: 
Monday, May 15, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Delafloxacin, Priority review, Partnership, Infection, Vaborbactam, Patient, Meropenem, Therapy, Health Canada, Pharmaceutical industry, Melinta Therapeutics

Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective products.

Key Points: 
  • Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective products.
  • Under the terms of the agreement, Xediton is responsible for the registration and commercialization of these products in Canada.
  • “We are very pleased to partner with Melinta to bring these life-saving products to Canada.
  • “We’re thrilled to enter into this partnership with Xediton, a recognized leader in specialty care pharmaceuticals in Canada.

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Retrieved on: 
Tuesday, September 20, 2022
People, CRKP, Group, World, Klebsiella pneumoniae, Health, KPC, Infection, HKEX, Prevalence, LLC, Hospital-acquired pneumonia, Commonwealth, Klebsiella, HAP, Republic, World Health Organization, Holding, Meropenem, Partnership, Menarini, Therapy, Patient, Cancer, Contributor License Agreement, Vaborbactam, Injection, Philippe Ciais, CRE, Toxic shock syndrome, License, Urinary tract infection, Marketing, Union, Cutis marmorata telangiectatica congenita, Mortality, Serine, Antibiotics, Pharmaceutical industry, Hospital, Meropenem/vaborbactam, Melinta Therapeutics

Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem(meropenem and vaborbactam) in the People's Republic of China (China).

Key Points: 
  • Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem(meropenem and vaborbactam) in the People's Republic of China (China).
  • This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enterobacterales (CRE).
  • According to China Antimicrobial Surveillance Network (CHINET), theincidence ofcarbapenem-resistantKlebsiella pneumoniae (CRKP) infections has experienced a steep increase in the last 10 years.
  • "We are excited to partner with Menarini to develop and commercialize Vaboremin China and bring better treatment options to patients with severe ailments.

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Retrieved on: 
Tuesday, September 20, 2022
People, CRKP, Group, World, Klebsiella pneumoniae, Health, Minocycline, KPC, Infection, HKEX, Prevalence, LLC, Hospital-acquired pneumonia, Commonwealth, Klebsiella, HAP, World Health Organization, Holding, Republic, Meropenem, Partnership, Menarini, Therapy, Patient, Cancer, Contributor License Agreement, Vaborbactam, Injection, Philippe Ciais, CRE, Toxic shock syndrome, License, Urinary tract infection, Marketing, Union, Cutis marmorata telangiectatica congenita, Mortality, Multimedia, Serine, Antibiotics, Pharmaceutical industry, Hospital, Meropenem/vaborbactam, Melinta Therapeutics

Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China).

Key Points: 
  • Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China).
  • This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enterobacterales (CRE).
  • According to China Antimicrobial Surveillance Network (CHINET), theincidence ofcarbapenem-resistantKlebsiella pneumoniae (CRKP) infections has experienced a steep increase in the last 10 years.
  • "We are excited to partner with Menarini to develop and commercialize Vaborem in China and bring better treatment options to patients with severe ailments.

Atomwise Appoints Gavin Hirst, Ph.D., as Chief Scientific Officer

Retrieved on: 
Wednesday, September 14, 2022
Software, Biotechnology, Nanotechnology, Pharmaceutical, Health, Artificial Intelligence, Health Technology, Technology, Lists of diseases, II, PAK, Entrepreneurship, Food, Inflammatory bowel disease, Psoriasis, SYK, Meropenem, Colorectal cancer, Senior, Secondary research, Therapy, Deep learning, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vaborbactam, CEO, Technology, Interim, Degenerative disease, Turning Point, Artificial intelligence, Takeda, IND, Janssen, Bristol Myers Squibb, Drug discovery, DLBCL, Pharmaceutical industry, Chemistry

Atomwise , a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer.

Key Points: 
  • Atomwise , a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer.
  • Gavin brings deep expertise in structure- and fragment-based drug discovery, and a fantastic track record in driving those initial discoveries to become new medicines to help patients.
  • In his new role, Dr. Hirst will set the companys strategic vision for drug discovery and provide scientific oversight of Atomwises research and development pipeline.
  • Atomwise is a technology-enabled pharmaceutical company leveraging the power of AI to revolutionize small molecule drug discovery.

Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.

Retrieved on: 
Wednesday, July 27, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Restore, Physician, DFC, U.S. Securities and Exchange Commission, Food, CEO, SAN, Fungemia, Forward-looking statement, EMA, Partnership, Private Securities Litigation Reform Act, Securities Act of 1933, Securities Exchange Act of 1934, NDA, Risk, Infection, Therapy, Safety, COVID-19, AstraZeneca, Respect, Mycosis, Minocycline, Prescription Drug User Fee Act, Injection, European Medicines Agency, Review, Caspofungin, FDA, Security (finance), Standard of care, Patient, CDTX, Nasdaq, Collaboration, CMC, Tavarua, LLC, Drug Quality and Security Act, Meropenem, Vaborbactam, QIDP, PDUFA, State, Bank, Pharmaceutical industry, EU, Melinta Therapeutics

The FDA has previously granted Qualified Infectious Disease Product (QIDP) designation to rezafungin for injection which confers priority review of the NDA.

Key Points: 
  • The FDA has previously granted Qualified Infectious Disease Product (QIDP) designation to rezafungin for injection which confers priority review of the NDA.
  • The NDA submission for rezafungin was based on positive results from Cidaras global ReSTORE Phase 3 and STRIVE Phase 2 trials.
  • The NDA submission for rezafungin for the treatment of candidemia and invasive candidiasis is an important milestone for Cidara, said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara.
  • Dr. Stein added, This transaction eliminates the need for Cidara to build commercial infrastructure to launch rezafungin in the U.S.

Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics

Retrieved on: 
Wednesday, April 6, 2022
Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Risk, Hypoglycemia, Therapy, Meropenem, First-degree atrioventricular block, Clonidine, Blood pressure, Cardiac arrest, NYHA, III, Allergy, Moyamoya disease, Diabetes, Angina, Diltiazem, Hyperthyroidism, Vaborbactam, Cardiogenic shock, AstraZeneca, Heart, Patient, Hypertension, Bradycardia, Peripheral artery disease, CEO, Adrenaline, Sinus node dysfunction, Pheochromocytoma, LLC, Heart block, Acquisition, Stroke, Verapamil, Injection, Castleman disease, Heart failure, Purkinje fibers, Digitalis, FDA, Minocycline, Infarction, Hypersensitivity, Pharmaceutical industry, Medical device, Melinta Therapeutics

We will continue to aggressively pursue portfolio expansion that aligns with our mission of providing innovative therapies for acute and life-threatening illnesses.

Key Points: 
  • We will continue to aggressively pursue portfolio expansion that aligns with our mission of providing innovative therapies for acute and life-threatening illnesses.
  • We are extremely proud of our work to provide access to this lifesaving medication, said Michael Anderson, CEO, New American Therapeutics.
  • Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses.
  • At Melinta, were visionaries dedicated to innovation while staying grounded in what matters most: patients.